Print Page  Close Window
Investor Overview
Company Overview

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital c... More >>

Recent News
12/17/14PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX™ Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules
Further Enhances Interpace Diagnostics' Thyroid Cancer Test Offering PARSIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Over 525,000 thyroid FNA's (fine needle aspirates) are performed annually and up to 30% of t... 
Printer Friendly Version
11/03/14PDI Reports 2014 Third Quarter Financial Results; Acquires RedPath Integrated Pathology
Management Will Host Conference Call Today November 3 at 8:00 am ET PARSIPPANY, N.J., Nov. 3, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the fiscal third quarter ended September 30, 2014. Developments during the quarter and recent weeks subsequent to the quarter include: Revenue of $29.2 million for the third quarter of 2014 in line with our expectations Two significant commercialization service contracts with a total value of ap... 
Printer Friendly Version
11/03/14PDI Expands Molecular Diagnostics Business with RedPath Integrated Pathology Acquisition
Interpace Diagnostics Enhances Oncology Diagnostic Capabilities with PathFinderTG® Pancreas and Additional Molecular Tests for Gastrointestinal Cancer PARSIPPANY, N.J., Nov. 3, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the acquisition of RedPath Integrated Pathology, a molecular diagnostics company helping physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG® ... 
Printer Friendly Version
10/31/14PDI, Inc. Announces Date & Time Change for Third Quarter Financial Results Conference Call
PARSIPPANY, N.J., Oct. 31, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq:PDII) today announced that it has adjusted the date and time it will release its third quarter 2014 financial results and operational highlights. The company will now release its results on Monday, November 3, 2014 and will host a conference call on Monday, November 3 at 8:00 a.m. Eastern Time to discuss the results.   Access information: Date: Monday, November 3, 2014 Time... 
Printer Friendly Version
More >>

Primary IR Contact
Doug Sherk
EVC Group, Inc.
Phone: 415.652.9100

Stock Quote
PDII (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Change (%) Stock is Up 0.08 (5.23%)
Data as of 12/22/14 2:58 p.m. ET
Minimum 20 minute delay
Refresh quote
Events and Presentations
Investor Presentation November 2014
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.